Retatrutide vs Amycretin: Triple Agonist vs GLP-1/Amylin Heavyweight
By FormBlends Medical Team · Last updated: April 25, 2026
Retatrutide is still the pure upside trade. Amycretin is the more strategic mechanism bet if you think the market will reward GLP-1 plus amylin programs for how they feel in practice, not just how hard they drive scale weight. Right now retatrutide looks bigger. Amycretin looks more nuanced.
How to Use This Comparison
Use this comparison as a decision aid, not a prescription shortcut. Retatrutide is a GLP-1/GIP/glucagon program; amycretin is GLP-1/amylin. Retatrutide is usually a better fit for readers focused on maximum efficacy upside in late-stage obesity drug development, while Amycretin (Zenagamtide) is usually a better fit for readers who think the next winner may be the one that balances efficacy with a smarter tolerability story. Cost also matters: Retatrutide is listed at Trial-stage asset; launch pricing unknown, while Amycretin (Zenagamtide) is listed at Trial-stage asset; launch pricing unknown. Because this comparison is framed as an either-or decision, the safety question is which option fits your health history, side-effect tolerance, and access path.
PubMed evidence trail
Research sources used to frame this page
For Retatrutide vs Amycretin: Triple Agonist vs GLP-1/Amylin Heavyweight, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
Retatrutide vs Amycretin: Triple Agonist vs GLP-1/Amylin Heavyweight should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Head-to-Head Comparison
Retatrutide
Pipeline Compound
Strengths
- One of the highest-conviction efficacy assets in obesity
- Backed by Lilly and already central to the next-wave narrative
- Multi-receptor biology gives it unusually broad ambition
Weaknesses
- Aggressive mechanism mix can create tolerability anxiety
- Still needs to convert promise into a clean commercial launch
Best For
Readers focused on maximum efficacy upside in late-stage obesity drug development.
Typical Cost
Trial-stage asset; launch pricing unknown
Amycretin (Zenagamtide)
Pipeline Compound
Strengths
- Phase 3 program tied to Novo's amylin strategy
- GLP-1/amylin framing gives it a cleaner differentiation story than another plain GLP-1
- Could matter a lot if the market shifts toward tolerability and body-composition quality
Weaknesses
- Has less broad public mindshare than retatrutide
- Needs to prove that the amylin angle translates into meaningful market separation
Best For
Readers who think the next winner may be the one that balances efficacy with a smarter tolerability story.
Typical Cost
Trial-stage asset; launch pricing unknown
Key Differences
- 1Retatrutide is a GLP-1/GIP/glucagon program; amycretin is GLP-1/amylin
- 2Retatrutide is judged mainly on efficacy ceiling, while amycretin is judged on whether amylin changes the quality of outcomes
- 3Lilly is pushing the broadest metabolic ambition here, while Novo is leaning into a differentiated satiety pathway
- 4Both are late-stage, but they represent different bets on what the post-Wegovy market rewards
Frequently Asked Questions
What is the difference between Retatrutide and Amycretin (Zenagamtide)?
Retatrutide is a GLP-1/GIP/glucagon program; amycretin is GLP-1/amylin. Retatrutide is judged mainly on efficacy ceiling, while amycretin is judged on whether amylin changes the quality of outcomes.
Which is more effective, Retatrutide or Amycretin (Zenagamtide)?
Retatrutide is still the pure upside trade. Amycretin is the more strategic mechanism bet if you think the market will reward GLP-1 plus amylin programs for how they feel in practice, not just how hard they drive scale weight. Right now retatrutide looks bigger. Amycretin looks more nuanced.
How much does Retatrutide cost compared to Amycretin (Zenagamtide)?
Retatrutide typically costs Trial-stage asset; launch pricing unknown, while Amycretin (Zenagamtide) typically costs Trial-stage asset; launch pricing unknown.
Who should choose Retatrutide over Amycretin (Zenagamtide)?
Retatrutide is best for: Readers focused on maximum efficacy upside in late-stage obesity drug development.. Amycretin (Zenagamtide) is best for: Readers who think the next winner may be the one that balances efficacy with a smarter tolerability story..
Ready to get started?
Connect with a licensed provider who can help you decide between Retatrutide and Amycretin (Zenagamtide) based on your goals, health history, and budget.